Kathy Smith

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

P. Kalra, D. McAuley, G. Glenn, 2021, The New England journal of medicine.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

D. Moodley, S. Madhi, V. Shinde, 2021, The New England journal of medicine.

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

J. Bradley, P. Kalra, G. Glenn, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

N. Patel, G. Glenn, Gale Smith, 2023, The New England journal of medicine.

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373

N. Patel, G. Glenn, Gale Smith, 2023, Vaccine.

Human infection due to recombinant vaccinia-rabies glycoprotein virus.

C. Hanlon, C. Rupprecht, M. Niezgoda, 2001, The New England journal of medicine.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant

P. Kalra, D. McAuley, G. Glenn, 2021, medRxiv.